Eledon Pharmaceuticals Income Statement (2013-2017) | ELDN

Income Statement Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017
Operating items
Research & Development 3.56M4.39M2.83M3.80M10.56M5.86M8.49M7.73M7.93M9.89M6.16M1.04M0.31M
Selling, General & Administrative 1.34M1.49M3.60M2.46M2.74M3.13M3.42M3.34M3.55M3.68M3.15M2.72M3.59M
Operating Expenses 4.89M5.88M6.42M6.26M13.30M8.98M11.91M11.07M11.48M13.57M9.31M3.76M3.89M
Operating Income -5.55M-4.89M-5.88M-6.42M-6.26M-13.30M-8.98M-11.91M-11.07M-11.48M-13.57M-9.31M-3.76M-3.89M
EBIT -5.55M-4.89M-5.88M-6.42M-6.26M-13.30M-8.98M-11.91M-11.07M-11.48M-13.57M-9.31M-3.76M-3.89M
Non-operating items
Interest & Investment Income 0.04M0.03M0.03M0.05M0.04M0.03M0.05M0.06M0.05M0.05M0.04M0.02M0.03M
Other Non Operating Income 0.04M0.05M
Net income details
EBT -5.55M-4.85M-5.85M-6.39M-6.21M-13.26M-8.96M-11.85M-11.02M-11.43M-13.53M-9.27M-3.74M-3.87M
Profit After Tax -5.53M-4.85M-5.85M-6.39M-6.21M-13.26M-8.96M-11.85M-11.02M-11.43M-13.53M-9.27M-3.74M-3.87M
Income from Continuing Operations -5.55M-4.85M-5.85M-6.39M-6.21M-13.26M-8.96M-11.85M-11.02M-11.43M-13.53M-9.27M-3.74M-3.87M
Consolidated Net Income -5.55M-4.85M-5.85M-6.39M-6.21M-13.26M-8.96M-11.85M-11.02M-11.43M-13.53M-9.27M-3.74M-3.87M
Income towards Parent Company -5.55M-4.85M-5.85M-6.39M-6.21M-13.26M-8.96M-11.85M-11.02M-11.43M-13.53M-9.27M-3.74M-3.87M
Net Income towards Common Stockholders -5.54M-4.85M-5.85M-6.39M-6.21M-13.26M-8.96M-11.85M-11.02M-11.43M-13.53M-9.27M-3.74M-3.87M
Additional items
EPS (Basic) -13.32-9.79-11.68-2.71-0.96-0.59-0.40-0.53-0.49-0.51-173.73-113.97-9.76-9.35
Shares Outstanding (Weighted Average) 0.42M0.50M0.50M2.36M6.47M22.38M22.42M22.54M22.48M22.63M0.08M0.08M0.38M0.41M4.15M6.94M
EBITDA -5.55M-4.89M-5.85M-6.39M-6.21M-13.26M-8.96M-11.84M-11.08M-11.38M-13.52M-9.27M-3.74M-3.87M